FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
-19.31%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$1.38B
AUM Growth
+$1.38B
(-39%)
Cap. Flow
-$655M
Cap. Flow
% of AUM
-47.52%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
1
Reduced
3
Closed
1
Top Buys
| 1 |
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
|
$21.2M |
Top Sells
| 1 |
Moderna
MRNA
|
$333M |
| 2 |
AXLA
Axcella Health Inc. Common Stock
AXLA
|
$293M |
| 3 |
Sana Biotechnology
SANA
|
$32.1M |
| 4 |
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
|
$18M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Moderna
MRNA
$9.37B
| $998M | 72.47% | 9,666,038 -3,220,705 | -25% | -$333M |
|
|
2
Sana Biotechnology
SANA
$777M
| $96.8M | 7.02% | 25,001,856 -8,288,162 | -25% | -$32.1M |
|
3
Foghorn Therapeutics
FHTX
$286M
| $63.4M | 4.6% | 12,674,120 | – | – |
|
|
OMGA
4
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $62.8M | 4.56% | 29,225,579 | – | – |
|
5
Seres Therapeutics
MCRB
$166M
| $55M | 3.99% | 23,117,045 | – | – |
|
6
Denali Therapeutics
DNLI
$2.23B
| $54M | 3.92% | 2,619,968 | – | – |
|
|
EVLO
7
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $31.1M | 2.26% | 7,932,624 +5,411,255 | +215% | +$21.2M |
|
|
AXLA
8
DELISTED
Axcella Health Inc. Common Stock
AXLA
| $12.2M | 0.89% | 1,170,059 -28,081,486 | -96% | -$293M |
|
|
SYRS
9
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $3.93M | 0.29% | 993,848 | – | – |
|
|
SGTX
10
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| – | – | -797,720 | Closed | -$18M |
|